Kiniksa will now focus its development efforts on the IL-1 blocker KPL-387, which it is testing for recurrent pericarditis ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...

Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors.

Clinical validation of the Azymetric platform is demonstrated by the accelerated approval of Ziihera® (zanidatamab-hrii), a ...

Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma ...

Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...

The FDA accepted odronextamab’s biologics license application resubmission for relapsed/refractory follicular lymphoma after ...

Regarding patients with HER2-negative, estrogen receptor (ER)-positive breast cancer, the phase 3 KEYNOTE-756 study is ...

An expert shares information on a pair of noteworthy active trials in breast cancer that patients should be aware of.

When combined with chemotherapy, cetuximab shows promising efficacy for optimizing treatment strategies for patients with ...

Adding obinutuzumab to standard therapy for active lupus nephritis led to significantly higher rates of complete renal ...